1. No link between type I interferon autoantibody positivity and adverse reactions to COVID-19 vaccines
- Author
-
Ahmet Yalcinkaya, Marco Cavalli, Axel Cederholm, Maribel Aranda-Guillén, Anish Behere, Hedvig Mildner, Tadepally Lakshmikanth, Laura Gonzalez, Constantin Habimana Mugabo, Anette Johnsson, Olov Ekwall, Olle Kämpe, Sophie Bensing, Petter Brodin, Pär Hallberg, Mia Wadelius, and Nils Landegren
- Subjects
Immunologic diseases. Allergy ,RC581-607 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Type I interferons act as gatekeepers against viral infection, and autoantibodies that neutralize these signaling molecules have been associated with COVID-19 severity and adverse reactions to the live-attenuated yellow fever vaccine. On this background, we sought to examine whether autoantibodies against type I interferons were associated with adverse events following COVID-19 vaccination. Our nationwide analysis suggests that type I interferon autoantibodies were not associated with adverse events after mRNA or viral-vector COVID-19 vaccines.
- Published
- 2024
- Full Text
- View/download PDF